AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01658995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
Trial: NCT02811341
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01165476
Drug: Treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release tablets. One 1mg tablet per period. Two total doses.
Trial: NCT02726386
Drug: ND0612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Trial: NCT03885388
Drug: MTX+ACTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination use of methotrexate and actinomycin
Trial: NCT01226524
Drug: Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
Trial: NCT04073134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Trial: NCT01863355
Drug: B0 group: bolus 0.6mcg/kg without background infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01863355
Drug: BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01863355
Drug: BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03604549
Drug: Lipiodol UF
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
Trial: NCT04432207
Drug: Standard of care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy to be administered according to the prescribing information.
Trial: NCT00678327
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00678327
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00678327
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT05303961
Drug: SA001 1,080mg or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Trial: NCT05303961
Drug: SA001 1,080mg or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Trial: NCT01822340
Drug: HM10560A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly HM10560A
Trial: NCT00860600
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
Trial: NCT01493596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of water mixed with juice will be administered.
Trial: NCT01030094
Drug: Normal control
RxNorm normalized name: Precision, Normal Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Healthy female participants will be observed in Normal control group.
Trial: NCT00027417
Drug: Liothyronine sodium/triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02730455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT02004067
Drug: Refresh Endura
RxNorm normalized name: Refresh Endura
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refresh Endura is a topical lubricant produced by Allergan, Inc.
Trial: NCT04006873
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per description in arms
Trial: NCT04326933
Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
Trial: NCT02339740
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00645944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or inactive substance (sugar pill)taken each night for all weeks of the study
Trial: NCT02260258
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00528333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
Trial: NCT03693833
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo tablets of 10mg each
Trial: NCT02875028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03944109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Trial: NCT04405739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule
Trial: NCT01436643
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
Trial: NCT03825744
Drug: Placebo+Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00940251
Drug: Mersina
RxNorm normalized name: Yersinia enterocolitica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, 3g/day, 3 months
Trial: NCT02176057
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00198536
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03427801
Drug: Erythropoiesis-Stimulating Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erythropoiesis-stimulating agent: Mircera or Darbepoietin
Trial: NCT03680261
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
Trial: NCT00562120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
Trial: NCT04975724
Drug: Liposom Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
Trial: NCT00923598
Drug: 0.1% and 0.4% perineural ropivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
Trial: NCT03799822
Drug: Vitamin K Antagonist - Drug
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with a vitamin K antagonist
Trial: NCT01129960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets will be used.
Trial: NCT01337596
Drug: LY2951742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01337596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01652586
Drug: dexmedetomidine-remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01652586
Drug: midazolam-remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01362296
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral once daily
Trial: NCT02452528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568711
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a 5-day course of 100 mg bid doses of doxycycline
Trial: NCT03168906
Drug: NEOD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
Trial: NCT03168906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline bag
Trial: NCT01008007
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
Trial: NCT04108962
Drug: Fasenra, 30 Mg/mL Subcutaneous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL5 receptor alpha monoclonal antibody
Trial: NCT01465568
Drug: bisphosphonates
RxNorm normalized name: Bisphosphonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continue present bisphosphonate treatment
Trial: NCT00349401
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00549341
Drug: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100U vials, doses ranged from 50U-200U, single injection.
Trial: NCT01696565
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable
Trial: NCT02335372
Drug: Acetic Acid
RxNorm normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
Trial: NCT00697801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered by nebulization twice daily for 6 weeks
Trial: NCT02381249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
Trial: NCT02485158
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
Trial: NCT01347008
Drug: Placebo (Sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
Trial: NCT00030407
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
Trial: NCT00535041
Drug: Chemotherapy, radiation therapy & surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiation and chemotherapy
Trial: NCT00097110
Drug: Vitamin C and E
RxNorm normalized name: Balanced B-Complex with Vitamin C and E
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00122447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD
Trial: NCT03432091
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
Trial: NCT00883935
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
Trial: NCT00814606
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
Trial: NCT03084809
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
Trial: NCT00799708
Drug: Comparator: Estrace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
Trial: NCT00880334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day every day
Trial: NCT03343639
Drug: Matching Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT00560924
Drug: estradiol, 25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01613729
Drug: Rosuvastatin 5 mg
RxNorm normalized name: rosuvastatin 5 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5 mg
Trial: NCT01613729
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00812318
Drug: GSK1265744 10 mg oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744
Trial: NCT00812318
Drug: GSK1265744 5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 5mg tablet, fasted
Trial: NCT00812318
Drug: GSK1265744 5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 5mg tablet, fed
Trial: NCT01091766
Drug: intravenous injection of test solution
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
Trial: NCT01848210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin + troxerutin placebo-matching tablets
Trial: NCT04983524
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard control intracanal medicament
Trial: NCT04592419
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT03389763
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a rate of infusion will be increased by 50% every 5 minutes
Trial: NCT01411111
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: days 1-14
Trial: NCT01411111
Drug: GSK2190915 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x30mg tablet, days 8-14
Trial: NCT01411111
Drug: GSK2190915 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x100mg tablet, days 8-14
Trial: NCT01661439
Drug: low molecular weight heparin (enoxeparine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
Trial: NCT03171415
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
Trial: NCT03171415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
Trial: NCT03803254
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT03562949
Drug: Test Product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Trial: NCT03562949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Product
Trial: NCT00160888
Drug: sodium nitroprusside, bradykinin, acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03460158
Drug: Restylane-L®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
Trial: NCT03460158
Drug: Restylane-L® Lyft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
Trial: NCT03460158
Drug: Restylane Silk®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Trial: NCT01497132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02249117
Drug: BIWH 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00201396
Drug: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction C/T + CCRT
Trial: NCT03428945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet identical to active drug
Trial: NCT03496298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: SC
Trial: NCT00942734
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet (5 mg) by mouth every day of each 28 day study cycle.
Trial: NCT01341470
Drug: LY2495655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously or subcutaneously
Trial: NCT01341470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously or subcutaneously
Trial: NCT05167617
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
Trial: NCT00108550
Drug: Inert placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
Trial: NCT00451490
Drug: Fluoxentine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01257191
Drug: Diesel Exhaust Particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: source: diesel engine
Trial: NCT01257191
Drug: Fine Concentrated Ambient Particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: source: concentrated ambient air
Trial: NCT01257191
Drug: Ultrafine Concentrated Ambient Particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: source: concentrated ambient air
Trial: NCT00776568
Drug: Anti-hypertensive drugs
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
Trial: NCT00605176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.